Navigation Links
Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Date:10/1/2007

rmone independent, non-metastatic prostate cancer.

The Company also has a robust pipeline of additional products cleared by FDA for early stage clinical trials in five other cancers beyond brain and prostate cancers.

For further information, please visit the company web site at http://www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the uncertainties of litigation in general and, specifically litigation involving intellectual property claims and securities class action claims that have been filed against the Company. Additional information on these and other factors which could affect the company's results is included in its Securities and Exchange Commission ("SEC") filings and its filings pursuant to its listing on the Alternative Investment Market of the London Stock Exchange ("AIM"). Finally, there may be other factors not mentioned above or included in the company's SEC filings and/or AIM filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Northwestern Mutual, American Family make Computerworlds best IT workplaces
2. Northwestern adds to its Imago microscope
3. Imago microscope leads to Northwestern research advance
4. Northwest Wis. Manufacturing Outreach Center honored by DOC, NIST
5. Speaker announces business members of IT Task Force
6. Doyle announces technology tax credits for Berbee
7. Doyle announces new energy, global warming policies
8. Doyle announces $80M renewable energy strategy
9. GE announces first installation of Discovery VCT
10. UWM announces winners of RGI awards
11. Third Wave announces two senior management appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...ary Advocates Widespread Screening of Truck Driver...ep Apnea, Advanced Brain Monitoring,s Apnea Risk E...es Increase Employee Productivity; Minimize Litiga...s, one main safety,issue that transportation compa...s a driver spent behind the wheel. After laws were...
...IDGEWATER, Mass., Sept. 5 Pressure,BioSciences, I...eceived,approval to CE Mark the Barocycler NEP2320...ven pressure cycling technology (PCT) instrument. ... a CB Scheme Test Certificate,and Report indicatin...mpliance with the IEC 61010-1 international standa...
...Former Portfolio Company is a Proven Leader at Dri...tal, LLC, a middle,market private equity firm that...fe sciences and healthcare services, industrial te...nounced the appointment of Michael L. Hurt,to the ...n of Mr. Hurt, CEO,of Altra Industrial Motion (Nas...
Other Biology Technology:Time For the Trucking and Heavy Machinery Industries to Wake Up! 2Time For the Trucking and Heavy Machinery Industries to Wake Up! 3Time For the Trucking and Heavy Machinery Industries to Wake Up! 4Time For the Trucking and Heavy Machinery Industries to Wake Up! 5Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 2Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 3Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 4Genstar Names Michael Hurt to Its Strategic Advisory Board 2
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
Breaking Biology News(10 mins):Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Research is vital to a cleaner, greener, low carbon future 2CCNY professor foresees rising Antarctic snowmelt 2Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 13979 1Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 13979 2Video 3A U S Department of Health and Human Services Joins Ad Council and Warner Bros Pictures to Combat Childhood Overweight and Obesity 56755 1Video 3A U S Department of Health and Human Services Joins Ad Council and Warner Bros Pictures to Combat Childhood Overweight and Obesity 56755 2Video 3A U S Department of Health and Human Services Joins Ad Council and Warner Bros Pictures to Combat Childhood Overweight and Obesity 56755 3Video 3A U S Department of Health and Human Services Joins Ad Council and Warner Bros Pictures to Combat Childhood Overweight and Obesity 56755 4Video 3A U S Department of Health and Human Services Joins Ad Council and Warner Bros Pictures to Combat Childhood Overweight and Obesity 56755 5Disability Rates Continue Steady Climb According to CDAs 2008 Disability Claims Review 56752 1Disability Rates Continue Steady Climb According to CDAs 2008 Disability Claims Review 56752 2Disability Rates Continue Steady Climb According to CDAs 2008 Disability Claims Review 56752 3
...he much-publicized "ABC" approach to HIV preventio...ause of its focus on abstinence-only sex education... political and religious conservatives against the...proach is sometimes credited as being responsible ...vocative debate in PLoS Medicine considers the two...
... new research report by The George Institute for I...d City Hospital and The University of Auckland, ha...fter stroke in the total population of Auckland, N...ibutes the improved survival rate to health care f...ission and brain imaging during the most severe ph...
... novel vascular targeting agent completely prevent... the mice tested in a preclinical study, providing...owth of tumors in bone, a common destination for a...searchers at The University of Texas M. D. Anderso...earch that this "Trojan Horse" agent, VEGF121/rGel...
Other Biology News:Did 'ABCs' cause Uganda's fall in HIV rates? 2New research shows big improvement in survival after stroke 2'Trojan Horse' agent halts bone metastasis in mice 2'Trojan Horse' agent halts bone metastasis in mice 3
Coating Solution Concentrate Kit from KPL
Flashlight-Trigger Solution from Assay Designs/Stressgen Bioreagents
...n 2-color real-time PCR detection system holds 48 ...of 48 LEDs independently excites fluorescence (470...todiodes detects emitted light (523-543 nm and 540...ers of the MJ Mini thermal cycler. System dimensio...
...Se Kit delivers a novel procedure for the uniform ...) labeling of whole genome DNA from small samples....and highly reproducible amplification and labeling...sists of a REPLI-g Mini Kit module (QIAGEN) and a ...
Biology Products: